BACKGROUND AND AIM: Interleukin (IL) 17 is a cytokine which exerts strong proinflammatory activities. In this study we evaluated changes in IL-17 expression in the inflamed mucosa and in the serum of patients with inflammatory bowel disease (IBD). METHODS: Tissue samples were obtained endoscopically or surgically from patients with ulcerative colitis (UC) (n=20), Crohn's disease (CD) (n=20), infectious colitis (n=5), ischaemic colitis (n=8), and normal colorectal tissues (n=15). IL-17 expression was evaluated by a standard immunohistochemical procedure. Serum IL-17 levels were determined by ELISA. IL-17 mRNA expression was analysed by reverse transcriptase-polymerase chain reaction. RESULTS: IL-17 expression was not detected in samples from normal colonic mucosa, infectious colitis, or ischaemic colitis. In the inflamed mucosa of active UC and CD patients, IL-17 expression was clearly detectable in CD3(+) T cells or CD68(+) monocytes/macrophages. The average number of IL-17(+) cells was significantly increased in active UC and CD patients compared with inactive patients. IL-17 mRNA expression was not detected in normal mucosa but was detectable in the mucosa from active UC and CD patients. IL-17 was not detected in the sera from normal individuals, infectious colitis, or ischaemic colitis patients but IL-17 levels were significantly elevated in IBD patients. CONCLUSIONS: IL-17 expression in the mucosa and serum was increased in IBD patients. It is likely that IL-17 expression in IBD may be associated with altered immune and inflammatory responses in the intestinal mucosa.
BACKGROUND AND AIM: Interleukin (IL) 17 is a cytokine which exerts strong proinflammatory activities. In this study we evaluated changes in IL-17 expression in the inflamed mucosa and in the serum of patients with inflammatory bowel disease (IBD). METHODS: Tissue samples were obtained endoscopically or surgically from patients with ulcerative colitis (UC) (n=20), Crohn's disease (CD) (n=20), infectious colitis (n=5), ischaemic colitis (n=8), and normal colorectal tissues (n=15). IL-17 expression was evaluated by a standard immunohistochemical procedure. Serum IL-17 levels were determined by ELISA. IL-17 mRNA expression was analysed by reverse transcriptase-polymerase chain reaction. RESULTS:IL-17 expression was not detected in samples from normal colonic mucosa, infectious colitis, or ischaemic colitis. In the inflamed mucosa of active UC and CDpatients, IL-17 expression was clearly detectable in CD3(+) T cells or CD68(+) monocytes/macrophages. The average number of IL-17(+) cells was significantly increased in active UC and CDpatients compared with inactive patients. IL-17 mRNA expression was not detected in normal mucosa but was detectable in the mucosa from active UC and CDpatients. IL-17 was not detected in the sera from normal individuals, infectious colitis, or ischaemic colitispatients but IL-17 levels were significantly elevated in IBD patients. CONCLUSIONS:IL-17 expression in the mucosa and serum was increased in IBD patients. It is likely that IL-17 expression in IBD may be associated with altered immune and inflammatory responses in the intestinal mucosa.
Authors: D V Jovanovic; J A Di Battista; J Martel-Pelletier; F C Jolicoeur; Y He; M Zhang; F Mineau; J P Pelletier Journal: J Immunol Date: 1998-04-01 Impact factor: 5.422
Authors: J Kennedy; D L Rossi; S M Zurawski; F Vega; R A Kastelein; J L Wagner; C H Hannum; A Zlotnik Journal: J Interferon Cytokine Res Date: 1996-08 Impact factor: 2.607
Authors: Z Yao; W C Fanslow; M F Seldin; A M Rousseau; S L Painter; M R Comeau; J I Cohen; M K Spriggs Journal: Immunity Date: 1995-12 Impact factor: 31.745
Authors: E Louis; J Belaiche; C van Kemseke; D Franchimont; D de Groote; V Gueenen; J Y Mary Journal: Eur J Gastroenterol Hepatol Date: 1997-10 Impact factor: 2.566
Authors: Z Yao; M K Spriggs; J M Derry; L Strockbine; L S Park; T VandenBos; J D Zappone; S L Painter; R J Armitage Journal: Cytokine Date: 1997-11 Impact factor: 3.861
Authors: F Fossiez; O Djossou; P Chomarat; L Flores-Romo; S Ait-Yahia; C Maat; J J Pin; P Garrone; E Garcia; S Saeland; D Blanchard; C Gaillard; B Das Mahapatra; E Rouvier; P Golstein; J Banchereau; S Lebecque Journal: J Exp Med Date: 1996-06-01 Impact factor: 14.307
Authors: G Fortin; K Yurchenko; C Collette; M Rubio; A-C Villani; A Bitton; M Sarfati; D Franchimont Journal: Clin Exp Immunol Date: 2009-01-23 Impact factor: 4.330
Authors: Dermot P B McGovern; Jerome I Rotter; Ling Mei; Talin Haritunians; Carol Landers; Carrie Derkowski; Deb Dutridge; Marla Dubinsky; Andy Ippoliti; Eric Vasiliauskas; Emebet Mengesha; Lily King; Sheila Pressman; Stephan R Targan; Kent D Taylor Journal: Inflamm Bowel Dis Date: 2009-06 Impact factor: 5.325
Authors: Ana M Dias; Alexandra Correia; Márcia S Pereira; Catarina R Almeida; Inês Alves; Vanda Pinto; Telmo A Catarino; Nuno Mendes; Magdalena Leander; M Teresa Oliva-Teles; Luís Maia; Cristina Delerue-Matos; Naoyuki Taniguchi; Margarida Lima; Isabel Pedroto; Ricardo Marcos-Pinto; Paula Lago; Celso A Reis; Manuel Vilanova; Salomé S Pinho Journal: Proc Natl Acad Sci U S A Date: 2018-05-02 Impact factor: 11.205